Banoxantrone
Based on 11 publication(s) in Google Scholar
Banoxantrone (AQ4N), as a prototype hypoxia selective cytotoxin, can be reduced to AQ4, a potent topoisomerase II inhibitor. Banoxantrone selectively kills hypoxic cells via an iNOS-dependent mechanism. Banoxantrone shows a potent cytotoxicity and hypoxia-selective effect enhanced by radiation.
The free form of the compound is prone to instability, it is advisable to consider the stable salt form (Banoxantrone dihydrochloride) that retains the same biological activity.
For research use only. We do not sell to patients.
- CAS No.: 136470-65-0
- Formula: C22H28N4O6
- Molecular Weight:444.48
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Other In-stock Forms of Banoxantrone
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Banoxantrone
More- ACS Nano. 2024 Jul 16;18(28):18412-18424. [Abstract]
- J Nanobiotechnology. 2026 Feb 1;24(1):200. [Abstract]
- Adv Sci (Weinh). 2026 Jan 18:e21886. [Abstract]
- Chem Eng J. 2025 Feb 1.
- J Control Release. 2025 Jul 10:383:113789. [Abstract]
- Mater Today Bio. 2026 May 17:38:103244. [Abstract]
- Mater Today Bio. 2025 Dec 15:36:102695. [Abstract]
- Acta Biomater. 2022 Sep 15:150:337-352. [Abstract]
- J Colloid Interface Sci. 2026 Apr 15:708:139847. [Abstract]
- Int J Nanomedicine. 2024 Apr 8:19:3367-3386. [Abstract]
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
Biological Activity
Description
IC50 & Target
[1]|
iNOS |
In Vitro
Banoxantrone (20 μM; 90 min) selectively induces cells damage in hypoxia T50/80 tumour cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 136470-65-0
-
Molecular Weight 444.48
-
Formula C22H28N4O6
-
SMILES
O=C1C2=C(C(O)=CC=C2O)C(C3=C(NCC[N+](C)(C)[O-])C=CC(NCC[N+](C)(C)[O-])=C13)=O
-
Synonyms
AQ4N
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
ACS Nano
Hypoxia-Specific Metal-Organic Frameworks Augment Cancer Immunotherapy of High-Intensity Focused Ultrasound. [Abstract]2024 Jul 16;18(28):18412-18424. PMID: 38949962 -
J Nanobiotechnology
HIFU postoperative hypoxia-activated metal-organic frameworks modulate the tumor microenvironment to augment immunotherapy. [Abstract]2026 Feb 1;24(1):200. PMID: 41622222 -
Adv Sci (Weinh)
Fluorinated Hypoxia-Responsive Aza-BODIPY for NIR-II FL/19F MR/PA Imaging and Phototherapy of Lung Cancer. [Abstract]2026 Jan 18:e21886. PMID: 41549220 -
-
J Control Release
Hypoxia-responsive albumin nanoparticles co-delivering banoxantrone and STING agonist enhance immunotherapy of high-intensity focused ultrasound. [Abstract]2025 Jul 10:383:113789. PMID: 40318808 -
Mater Today Bio
2026 May 17:38:103244. PMID: 42211060 -
Mater Today Bio
Hypoxia-specific metal-organic frameworks combined with lactate immunometabolism regulation augment anti-tumor immunity of HIFU. [Abstract]2025 Dec 15:36:102695. PMID: 41509979 -
Acta Biomater
Genetically engineered bacteria-mediated multi-functional nanoparticles for synergistic tumor-targeting therapy. [Abstract]2022 Sep 15:150:337-352. PMID: 35931281 -
J Colloid Interface Sci
Manganese-based metal-organic frameworks augment postoperative immunotherapy of high-intensity focused ultrasound. [Abstract]2026 Apr 15:708:139847. PMID: 41518922 -
Int J Nanomedicine
Folic Acid Functionalized AQ4N/Gd@PDA Nanoplatform with Real-Time Monitoring of Hypoxia Relief and Enhanced Synergistic Chemo/Photothermal Therapy in Glioma. [Abstract]2024 Apr 8:19:3367-3386. PMID: 38617794 -
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471
Purity & Documentation
References
[1]. Hejmadi MV, et al. DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells. Br J Cancer. 1996 Feb;73(4):499-505. [Content Brief]
[2]. Mehibel M, et al. Radiation enhances the therapeutic effect of Banoxantrone in hypoxic tumour cells with elevated levels of nitric oxide synthase. Oncol Rep. 2016 Apr;35(4):1925-32. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Banoxantrone Related Classifications
HY-13562 Related Classifications
Powered by Bioz